Exclusive: Backed by Illumina, Broken String Biosciences raises $15M to find off-target gene edits
Broken String Biosciences has raised $15 million for its off-target sequencing service for gene editing companies.
The Series A round was led by Illumina Ventures and Mérieux Equity Partners and included HERAN Partners, Tencent and Dieter von Holtzbrinck Ventures. Mérieux’s Yoann Bonnamour and Illumina Ventures’ Arnaud Autret have joined Broken String’s board.
Broken String’s sequencing platform service is tailored for gene editing companies and their contract research organizations to find off-target edits as they develop new therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.